The two-year postoperative clinical data showed OsteoSponge equivalent to recombinant bone morphogenic protein in achieving interbody fusion. Patients who received OsteoSponge also reported significantly less leg pain than patients who received rhBMP-2.
The product is used in conjunction with patients’ own bone marrow aspirate. Since its release, OsteoSponge has been implanted more than 100,000 times.
Related Articles on Spine Surgery:
Surgery for Herniated Disc Within 6 Months of Symptom Appearance Shows Best Outcomes
Where Infuse Stands: 6 Points on the Controversial Spinal Fusion Product
Minimally Invasive Spine Surgery Registries Gather Support From Device Companies
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.